Alphatec Holdings Inc is expected to report Q3 2026 revenue of approximately $225.15 million and earnings per share of $0.10, with shares currently trading around $10.94 against an average analyst price target of $15.79.
Investors are primarily watching for surgical procedure growth and the adoption rate of the company's InformatiX platform, including the integration of EOS imaging and SafeOp technologies.
The medical technology firm has shown strong operating momentum in recent quarters, recently matching EPS expectations and exceeding revenue targets through increased surgeon adoption.
Market participants will also focus on the company's progress toward achieving sustained positive free cash flow and updates on the planned launch of the Valence robotics system.